

## Final Program

# IMARI

Interdisciplinary Meeting  
on Antimicrobial Resistance  
and Innovation

January 28-30, 2026 • Las Vegas, NV

An ASM and IDSA Collaboration



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY



[imari.org](http://imari.org)



**EMBLAVEO™**  
aztreonam and avibactam  
for injection (2 g)

TWO AGENTS COMBINED

AZTREONAM



AVIBACTAM


EXPLORE →

© 2025 AbbVie. All rights reserved. EMBLAVEO™ and its design are trademarks of Allergan Sales, LLC, an AbbVie company. US-EMB-240044 05/25

**NOW AVAILABLE TO ORDER**

## Table of Contents

Program Committee .....	3
Thank You to Our Sponsors .....	4
General Information .....	5
Scientific Program .....	6
Abstracts/Poster Sessions .....	16



## Thank You to Our Sponsors

The American Society for Microbiology and the Infectious Diseases Society of America acknowledge the following organizations for their support of the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI). On behalf of our leadership and members, we thank them for their financial support:

### Gold Supporters

---

**abbvie**

### Silver Supporters

---

**basilea**

### Bronze Supporters

---

 **Qpex**  
SHIONOGI Group Company

 **SHIONOGI**

### Industry Events

---

 **BIOMÉRIEUX**

 **abbvie**  
 **BD**

### Lanyard Sponsor

---

 **SeqCoast**  
GENOMICS

# General Information

## Registration and Name Badges

The registration desk will be in the Congo Foyer in the Sahara Las Vegas during posted registration hours. Participants may pick up name badges at the registration desk. A name badge is required for entry into all conference activities.

Participants' guests may not attend receptions, scientific sessions, poster sessions, lunches or coffee breaks.

## Registration Hours

### **Wednesday, January 28**

7 a.m.–7 p.m.

### **Thursday, January 29**

6:30 a.m.–5:30 p.m.

### **Friday, January 30**

7 a.m.–2 p.m.

## Abstracts

Abstracts presented at the conference will be available to view in the online [Poster & Abstract Gallery](#) for six months following the meeting. Access to the gallery is exclusive to IMARI attendees.

## Poster Sessions

The poster sessions will take place in the Nikko Room at the Sahara Las Vegas.

### **Poster Session #1**

Thursday, January 29  
12:30 p.m.–2:00 p.m.

### **Poster Session #2**

Friday, January 30  
10:45 a.m.–12:15 p.m.

## Networking Meals and Social Events

Registration includes attendance at the opening reception, lunches on Thursday and Friday and refreshment breaks.

## Certificate of Attendance

Certificates of Attendance can be downloaded after the conference. Participants will receive an email with a link to print their certificate approximately three days after the conference. *Note: Certificates of Attendance do not list individual session information.*

## Protecting The Science—Photo Policy

To protect the integrity of science, taking photos or videos of projected images of any session, slide or poster with any device is prohibited.

**We are committed to developing innovative antibacterial and antifungals to treat patients with severe and life-threatening infections**



## Events Code of Conduct

All attendees are expected to follow the [Event Codes of Conduct](#) to ensure a respectful and safe environment. This includes policies on behavior, professionalism, and ethics. Violation of the codes may result in removal from the meeting. Please refer to the ASM and IDSA websites for the complete codes.


## Social Media Etiquette

While attending the meeting, as well as when interacting on social media, ASM and

IDSA expect that all attendees will contribute to the professional atmosphere of the meeting. ASM, IDSA and the Program Committee reserve the right to remove, delete or block any individual or social media comments exhibiting behavior that detracts from or disrupts the scientific environment.

## Child Policy

Children are not permitted in session rooms, poster sessions, conference meals or social events. Please contact the hotel concierge to arrange for babysitting services in your hotel room.



## Taking on AMR, together

AMR is an urgent, global public health threat that demands collaborative action across industries, continents, disciplines, governments, and NGOs. It requires multiple, parallel efforts, including advancing research, shaping policy, and strengthening stewardship and surveillance systems.

That's why we are actively investing as an organization to meet this complex challenge and address unmet needs in AMR.

© 2026 Shionogi Inc. Florham Park, NJ 07932. All Rights Reserved.  
All trademarks are the property of their respective owners.  
USSH-0368 v1 01/26

# IMARI Scientific Program

(View the Program online [here](#).)

## Wednesday, January 28

### Workshop (Additional fee \$ and advanced registration required)

8 a.m.–12 p.m.	<b>Expert Symposium A: Microbiomes as Reservoirs, Catalysts, and Solutions for AMR</b> 📍 George I & II Moderators: Amy Mathers, M.D., D(ABMM), <i>University of Virginia</i> ; Jeff Freiberg, M.D., Ph.D., <i>Vanderbilt University Medical Center</i> <b>Opening Remarks</b> Speakers: Amy Mathers, M.D., D(ABMM), <i>University of Virginia</i> ; Jeff Freiberg, M.D., Ph.D., <i>Vanderbilt University Medical Center</i> <b>Genomics of AMR: Past, Present, and Future</b> Speaker: Derrick Crook, MBBCh, FRCP, FRCPath, <i>University of Oxford</i> <b>Accelerating Antibiotic Discovery with AI</b> Speaker: Cesar de la Fuente, Ph.D., <i>University of Pennsylvania</i> <b>Break</b> <b>Traveler Microbiomes as Windows into Antibiotic Resistance Spread</b> Speaker: Ashlee Earl, Ph.D., <i>Broad Institute</i> <b>Healthy Microbes Protecting Patients from AMR</b> Speaker: Mary Hayden, M.D., <i>Rush University</i> <b>Microbiomes as Reservoirs, Catalysts, and Solutions for AMR</b> Speaker: Michael Woodworth, M.D., MSc, <i>Emory University</i> <b>Questions &amp; Discussion</b>
----------------	--

### Workshop (Additional fee \$ and advanced registration required)

8 a.m.–12 p.m.	<b>Expert Symposium B: Translating Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Development and Clinical Utility</b> 📍 Louie I & II Moderators: Ryan Shields, Pharm.D., M.S., <i>Society of Infectious Diseases Pharmacists (SIDP)</i> ; Thomas Tängdén, M.D., Ph.D., <i>European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</i> ; David Andes, M.D., Ph.D., <i>University of Wisconsin-Madison</i> <b>Welcome and Overview of Key Objectives for PK-PD Expert Symposium</b> Speakers: Ryan Shields, Pharm.D., M.S., <i>Society of Infectious Diseases Pharmacists (SIDP)</i> ; Thomas Tängdén, M.D., Ph.D., <i>European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</i> ; David Andes, M.D., Ph.D., <i>University of Wisconsin-Madison</i>
----------------	---

10–8:55 a.m.	<b>From Target to Therapeutic: Early PK Considerations in Antimicrobial Drug Development</b> Speaker: Alexander Lepak, M.D., FIDSA, <i>University of Wisconsin</i>
8:55–9:40 a.m.	<b>Defining the Optimal Dose through Pre-Clinical PK-PD Modeling and a Pharmacometric Framework</b> Speaker: Sujata Bhavnani, Pharm.D., MSc, <i>Institute for Clinical Pharmacodynamics</i>
9:40–10:10 a.m.	<b>Networking Break</b>
10:10–10:40 a.m.	<b>Site-Specific PK-PD of Antimicrobials: From ELF to CNS</b> Speaker: Keith Rodvold, Pharm.D., FCCP, FIDSA, <i>University of Illinois</i>
10:40–11:10 a.m.	<b>A New Era of Oral Agents for MDR Pathogens: PK-PD Considerations</b> Speaker: Navaneeth Narayanan, Pharm.D., MPH, MS, BCIDP, MP, <i>Rutgers University</i>
11:10–11:40 a.m.	<b>Therapeutic Drug Monitoring: New Perspectives, Feasibility, and Applications for Patients with Difficult-to-Treat Infections</b> Speaker: Erin McCreary, Pharm.D., <i>University of Pittsburgh</i>
11:40 a.m.–12 p.m.	<b>Wrap Up, Questions, and Discussion</b>

12:30–1:30 p.m.	<b>Industry Sponsored Lunch Symposia - bioMérieux</b> 📍 George I & II   <b>From Empiricism to Precision: How Diagnostics Enable Optimal Use of Novel Therapeutics</b> Speaker: Ryan Shields, PharmD, M.S., <i>Pharmacist-Scientist, Associate Professor in the Department of Medicine, Division of Infectious Diseases</i>  The goal of this talk is to align clinical care, stewardship, microbiology and the antimicrobial pipeline towards optimal use of newly developed antibiotics aimed to treat multidrug-resistant bacterial pathogens.
3–5:15 p.m.	<b>Opening Session: Antimicrobial Resistance: Facing the Challenge Now</b> 📍 Congo I, II, III, & IV  <b>Opening Remarks</b> Speakers: Cesar A. Arias, M.D., MSc, Ph.D., <i>Houston Methodist and Weill Cornell Medical College, IMARI 2026 Co-Chair</i> ; Greg Moeck, Ph.D., <i>IMARI 2026 Co-Chair</i>
3:15–3:45 p.m.	<b>Antibiotics as Infrastructure for Civilization</b> Speaker: Kevin Outterson, J.D., LL.M., ESQ, CARB-X
3:45–4:15 p.m.	<b>Discovering New Antibiotics in the 21st Century</b> Speaker: Kim Lewis, Ph.D., <i>Northeastern University</i>
4:15–4:45 p.m.	<b>Fighting an Antimicrobial Resistant Infection: A Patient's Perspective</b> Speaker: Ella Balasa, <i>Patient Advocate</i>

4:45–5:15 p.m.	<b>Capturing the Global Burden of AMR: A Film by Dan Reed</b> Speaker: Dan Reed, Director, Amos Pictures
5:30–7 p.m.	<b>Opening Reception</b> 📍 Azilo

## Thursday, January 29

Concurrent Sessions	
7:30–8:45 a.m.	<p><b>Meet the Expert: PBP Occupancy: Challenges and Opportunities for Antimicrobial Discovery</b></p> <p>📍 Congo I, II, III, &amp; IV</p> <p>Moderators: Alita Miller, Ph.D., ArrePath Inc.; Laurent Poirel, Ph.D., University of Fribourg</p> <p><b>Optimizing PBP and <math>\beta</math>-lactamase Inhibition to Overcome <math>\beta</math>-lactam Resistance in Gram-Negative Bacteria</b> Speaker: Antonio Oliver, Ph.D., Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears</p> <p><b>Landscape and Phenotypic Determination of Synergistic PBP Occupancy Patterns in Gram-Negative Bacteria</b> Speaker: Jürgen Bulitta, Ph.D., St. Jude Children's Research Hospital</p>
7:30–8:45 a.m.	<p><b>Meet the Expert: Metallo-<math>\beta</math>-lactamases and MBL Inhibitors</b></p> <p>📍 George I &amp; II</p> <p>Moderators: Pranita Tamma, M.D., Johns Hopkins Hospital; Samuel Aitken, Pharm.D., Michigan Medicine</p> <p><b>How Much Do We Actually Know (and Don't Know) About Metallo-<math>\beta</math>-Lactamase Biochemistry and Host Specificity?</b> Speaker: Alejandro Vila, Ph.D., Universidad Nacional de Rosario</p> <p><b>Rational Design of Metallo-<math>\beta</math>-Lactamase Inhibitors</b> Speaker: Graciela Mahler, Ph.D., Universidad de la República</p>
7:30–8:45 a.m.	<p><b>Mentoring Session: Career Paths in AMR</b></p> <p>📍 Louie I &amp; II</p> <p>Moderators: Bill Shafer, Ph.D., Emory University School of Medicine; Harrison Lee, Ph.D., University of Pittsburgh</p> <p><b>Panel Discussion</b> Speakers: Judith Steenbergen, Ph.D., Scientific and Medical Affairs Consulting; Eric Brown, Ph.D., McMaster University; Pranita Tamma, M.D., M.H.S., University of Pennsylvania</p>

9–10:30 a.m.	<b>Plenary Session: New Antimicrobial Agents in The Pipeline: Early Clinical Development</b>
9–9:15 a.m.	<span data-bbox="360 169 560 197">📍 Congo I, II, III, &amp; IV</span> Moderators: <b>Karen Bush, Ph.D., Indiana University; Patricia Bradford, Ph.D., Antimicrobial Development Specialists, LLC</b>
9:15–10:30 a.m.	<b>Historical Overview of the Antimicrobial Pipeline: Success or Failure?</b> Speaker: <b>Karen Bush, Ph.D., Indiana University</b>
9:15–10:30 a.m.	<b>New Antimicrobial Agents</b> 9:15–9:30 a.m. <b>Compound SCY-247</b> Presenter: <b>David Angulo, M.D., SCYNEXIS, Inc.</b> 9:30–9:45 a.m. <b>Compound SER-155</b> Presenter: <b>Dennis Walling, M.D., Seres Therapeutics</b> 9:45–10 a.m. <b>Compound Zosurabipin</b> Presenter: <b>Michael Lobritz, M.D., Ph.D., Roche</b> 10–10:15 a.m. <b>Compound Turletricin/EL219</b> Presenter: <b>Taylor Sandison, M.D., MPH, Eion Therapeutics</b> 10:15–10:30 a.m. <b>Compound FG-2101</b> Presenter: <b>Andrew Tomaras, Ph.D., Blacksmith Medicines</b>
10:30 a.m.–10:45 a.m.	<b>Morning Refreshment Break</b> <span data-bbox="360 784 444 816">📍 Nikko</span>
<b>Concurrent Sessions</b>	
10:45 a.m.–12:15 p.m.	<b>Symposium: Hot Topics in AMR Among Gram-Positive Bacteria</b> <span data-bbox="360 948 486 979">📍 Louie I &amp; II</span> Moderators: <b>Thomas Holland, M.D., MSc, Duke University; Ayesha Khan, Ph.D., UC Irvine School of Medicine</b> 10:45–11:15 a.m. <b>Mechanism of Lipopeptide Action</b> Speaker: <b>Yousif Shamoo, Ph.D., Rice University</b> 11:15–11:45 a.m. <b>Collateral Damage of Rifaximin Prophylaxis in VRE</b> Speaker: <b>Glen Carter, Ph.D., University of Melbourne</b> 11:45 a.m.–12:15 p.m. <b>Novel Biomimetic Nanomedicines and Nanovaccines for MRSA and Other Leading AMR Pathogens</b> Speaker: <b>Victor Nizet, M.D., University of California</b>
10:45 a.m.–12:15 p.m.	<b>Symposium: New Generation <math>\beta</math>-lactamase Inhibitor</b> <span data-bbox="360 1323 560 1354">📍 Congo I, II, III, &amp; IV</span> Moderators: <b>Robert Bonomo, M.D., Louis Stokes Cleveland Medical Center; William Miller, M.D., Houston Methodist Hospital</b> 10:45–11:15 a.m. <b><math>\beta</math>-lactamase Inhibitor Discovery</b> Speaker: <b>Olga Lomovskaya, Ph.D., Qpex</b>

11:15–11:45 a.m.	<p><b>Escape Mutants Against Novel Broad Spectrum BLIs: Microbiological and Clinical Implications</b> Speaker: Laurent Poirel, Ph.D., <i>University of Fribourg</i></p>
11:45 a.m.–12:15 p.m.	<p><b>Rationale for Pairing <math>\beta</math>-lactams with Inhibitors</b> Speaker: Tomefa Asempa, PharmD, <i>Hartford Hospital Center for Anti-Infective Research &amp; Development (CAIRD)</i></p>
10:45 a.m.–12:15 p.m.	<p><b>Symposium: Antifungal Discovery Near and Far</b></p>
	<p>📍 George I &amp; II Moderators: David Andes, M.D., Ph.D., <i>University of Wisconsin-Madison</i>; Minh-Hong Nguyen, M.D., <i>University of Pittsburgh</i></p>
10:45–11:15 a.m.	<p><b>Antifungal Resistance Gaps</b></p>
11:15–11:45 a.m.	<p>Speaker: Luis Ostrosky-Zeichner, M.D., <i>UTHealth Houston</i></p>
11:45 a.m.–12:15 p.m.	<p><b>Early Discovery Approaches and Promising Leads</b></p>
	<p>Speaker: Damian Krysan, M.D., Ph.D., <i>University of Iowa</i></p>
	<p><b>New Agents in Clinical Development</b></p>
	<p>Speaker: Andrej Spec, M.D., MSCI, <i>Washington University</i></p>
12:30–2:00 p.m.	<p><b>Poster Session #1</b></p>
	<p>📍 Nikko</p>
12:30–1:00 p.m.	<p><b>Lunch</b></p>
	<p>📍 Clyde and Nikko</p>
1:00–2:00 p.m.	<p><b>Industry Sponsored Lunch Symposia - AbbVie</b></p>
	<p>📍 George I &amp; II</p>
	<p><b>Review of the EMBLAVEO In Vitro and Clinical Data</b></p>
	<p>Speaker: Brandon Smith, M.D., PharmD, <i>University of Pittsburgh School of Medicine</i></p>
	<p>This session will provide an overview of the in vitro and clinical data supporting the use of EMBLAVEO.</p>
2:15–3:45 p.m.	<p><b>Symposium: Novel Insights into <math>\beta</math>-lactam Resistance in Gram-Positive Pathogens</b></p>
	<p>📍 George I &amp; II</p>
	<p>Moderators: Erin Duffy Ph.D., <i>Gates Foundation</i>; Cecilia Tran, Pharm.D., <i>Houston Methodist and Weill Cornell Medical College</i></p>
2:15–2:45 p.m.	<p><b>Convergent Pathways for Cell Envelope Defense Against Daptomycin and B-lactams: The Seesaw Effect</b></p>
	<p>Speaker: Kara Hood, Ph.D., <i>Houston Methodist Research Institute</i></p>

2:45–3:15 p.m.	<p><b>Mechanisms of Broad-spectrum <math>\beta</math>-lactam Resistance in <i>S. aureus</i></b>  <b>Speaker: Som Chatterjee, Ph.D., University of Maryland</b></p>
3:15–3:45 p.m.	<p><b>PBPs and <math>\beta</math>-lactam Resistance in Enterococci and Streptococci</b>  <b>Speaker: Louis Rice, M.D., Brown University</b></p>
2:15–3:45 p.m.	<p><b>Symposium: What is New in Antimicrobial Resistance Detection? AST for New Agents Against MDRO</b></p> <p>📍 Congo I, II, III, &amp; IV</p> <p><b>Moderators: Romney Humphries, Ph.D., D(ABMM), M(ASCP), Vanderbilt University Medical Center; Carey-Ann Burnham, Ph.D., Pattern Bioscience</b></p> <p><b>Diagnostics Considerations for Drug Development</b>  <b>Speaker: Robin Patel, M.D., Mayo Clinic</b></p> <p><b>Predicting Novel AMR Resistance Mechanisms through AI and WGS</b>  <b>Speaker: David Greenberg, M.D., University of Texas Southwestern</b></p> <p><b>Transcriptomics as a Tool to Predict Antibiotic Susceptibility</b>  <b>Speaker: Roby Bhattacharyya, M.D., Ph.D., Broad Institute-Harvard</b></p>
2:15–3:45 p.m.	<p><b>Symposium: Current Trends in Antifungal Resistance</b></p> <p>📍 Louie I &amp; II</p> <p><b>Moderators: Max Adelman, M.D., Houston Methodist; Mariana Castaneira, Ph.D., JMI Laboratories</b></p> <p><b><i>Candida</i> Heteroresistance</b>  <b>Speaker: Tobias Hohl, M.D., Ph.D., Memorial Sloan Kettering</b></p> <p><b>The Rise of <i>Candida auris</i></b>  <b>Speaker: Jeniel Nett, M.D., Ph.D., University of Wisconsin-Madison</b></p> <p><b>Resistance in <i>Aspergillus</i> and Related Molds</b>  <b>Speaker: Nathan Wiederhold, Pharm.D., University of Texas at San Antonio</b></p>
3:45–4:00 p.m.	<p><b>Afternoon Refreshment Break</b></p> <p>📍 Nikko</p>
4–5:15 p.m.	<p><b>Plenary Session</b></p> <p>📍 Congo I, II, III, &amp; IV</p> <p><b>Moderators: Greg Moeck, Ph.D., IMARI 2026 Co-Chair; Amy Mathers, M.D., D(ABMM), University of Virginia</b></p> <p><b>Outstanding Oral Abstract Presentations</b></p> <p>4–4:15 p.m.  <b>A Novel Mechanism of Ceftolozane–Tazobactam Resistance in <i>Pseudomonas aeruginosa</i> Mediated by L2 Beta-Lactamase</b>  <b>Presenter: Preeti Garai, Northwestern University</b></p>

4:15–4:30 p.m.

**Investigations on the Mechanism of Action of the Novel Anti-Fungal MBX-7591**

Presenter: Keyla Ramirez Soto, *Dartmouth Geisel School of Medicine*

4:30–4:45 p.m.

**Transferable B-lactam Resistance in Multidrug-Resistant *Enterococcus faecalis* Via Truncation of *pbp4* and Acquisition of a Novel PBP (PBP-4a) Gene**

Presenter: Guillermo Hoppe-Elsholz, *Weill Cornell Medical College*

4:45–5:15 p.m.

**The Ribosome as an Antibacterial Target**

Speaker: Alexander Mankin, DSc, Ph.D., *University of Illinois*

6:00–8:00 p.m.



**Industry Sponsored Evening Symposium – Becton Dickinson (BD)**

**NDM as a Signal: What a 460% Surge Reveals About AMR System Readiness**

📍 George I & II

Speakers: Romney Humphries, Ph.D., D(ABMM), M(ASCP), Director of the Division of Laboratory Medicine and Medical Director of the Microbiology Laboratory at Vanderbilt University, Professor of Pathology, Microbiology and Immunology, Lynn Connolly, M.D., Ph.D., Chief Medical Officer at QxPex, Maroya Walters, Ph.D, ScM, Captain in the U.S. Public Health Service, Epidemiologist and Antimicrobial Resistance Team Lead at CDC

The CDC's recent report of a 460% increase in New Delhi metallo-β-lactamase (NDM)-producing carbapenem-resistant Enterobacteriales (CRE) is more than a microbiologic anomaly – it's a stress test for our healthcare infrastructure. This symposium will use NDM as a case study to examine how a single resistance mechanism can expose systemic gaps across diagnostics, therapeutic innovation, stewardship, and public health policy.

Through a cross-functional lens, experts will explore how mechanism-level data can drive smarter detection, targeted therapy, and coordinated response. Attendees will gain actionable insights into how early warning signals like NDM can catalyze innovation and collaboration across sectors to strengthen AMR preparedness.

## Friday, January 30

Concurrent Sessions	
7:30–8:45 a.m.	<b>Meet the Expert: Best AMR Papers of 2025: AAC and JID</b> 📍 Congo I, II, III, & IV Moderators: Cesar A. Arias, M.D., Ph.D., M.S., <i>Editor in Chief of AAC</i> ; Cornelius (Neil) J. Clancy, M.D., <i>University of Pittsburgh</i> <b>Research Highlights: Selected Best Papers</b> Speakers: Ayesha Khan, Ph.D., <i>UC Irvine School of Medicine</i> ; Madison Stellfox, M.D., <i>University of Pittsburgh</i>
7:30–8:45 a.m.	<b>Meet the Expert: Non-Dilutive Push Funding: Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Pathways to Antimicrobial Clinical Efficacy (PACE), Gram-Negative Antibiotic Discovery Innovator (Gr-ADI)</b> 📍 George I & II Moderators: Erin Duffy Ph.D., <i>Gates Foundation</i> ; Patricia Bradford, Ph.D., <i>Antimicrobial Development Specialists, LLC</i> <b>Panel Discussion</b> Speakers: Su Chiang, Ph.D., <i>CARB-X</i> ; Beverley Isherwood, Ph.D., <i>PACE</i> ; Erin Duffy Ph.D., <i>Gates Foundation</i>
7:30–8:45 a.m.	<b>Mentoring Session: NIH Grants in AMR</b> 📍 Louie I & II Moderators: Robert Bonomo, M.D., <i>Louis Stokes Cleveland Medical Center</i> ; Pranita Tammar, M.D., <i>Johns Hopkins Hospital</i> <b>NIH Grants in AMR</b> Speakers: Clayton Huntley, Ph.D., <i>NIH/NIAID</i> ; Michael Berney, Ph.D., <i>Chair AIRT, Albert Einstein College of Medicine</i>
7:30–8:45 a.m.	

Concurrent Sessions	
9–10:30 a.m.	<b>Symposium: Novel Dosing Strategies to Optimize Efficacy of New Antimicrobials Against MDR Pathogens</b> 📍 Louie I & II Moderators: Keith Rodvold, Pharm.D., <i>University of Illinois Chicago</i> ; Boudewijn DeJonge, Ph.D., <i>Shionogi</i> <b>Long-Acting Glycopeptides</b> Speaker: Cecilia Tran, Pharm.D., <i>Houston Methodist and Weill Cornell</i> <b>β-lactam – β-lactamase Inhibitors</b> Speaker: Milo Gatti, M.D., <i>University of Bologna</i> <b>Antifungals</b> Speaker: Alexander Lepak, M.D., <i>FIDSA, University of Wisconsin</i>
9–9:30 a.m.	
9:30–10 a.m.	
10–10:30 a.m.	

9–10:30 a.m.	<p><b>Symposium: Optimizing Clinical Trial Design for New Antibiotics</b></p> <p>📍 George I &amp; II</p> <p>Moderators: <i>Lilian Abbo, M.D., MBA, University of Miami &amp; Jackson Health System; Roby Bhattacharyya, M.D., Ph.D., Broad Institute-Harvard</i></p> <p><b>Don't Bac Down: Designing Great Clinical Trials in Bacteremia</b> Speaker: <i>Thomas Holland, M.D., MSc, Duke University</i></p> <p><b>Nosocomial Pneumonia/VAP</b> Speaker: <i>Richard Wunderink, M.D., Northwestern University</i></p> <p><b>Trials in Antifungals</b> Speaker: <i>Minh-Hong Nguyen, M.D., University of Pittsburgh</i></p>
9–10:30 a.m.	<p><b>Symposium: Antibiotic Discovery</b></p> <p>📍 Congo I, II, III, &amp; IV</p> <p>Moderators: <i>Alita Miller, Ph.D., ArrePath Inc.; Razi Kebriaei, Ph.D., Ohio State University</i></p> <p><b>Deep Learning for Antibiotic Discovery</b> Speaker: <i>James Collins, Ph.D., Broad Institute</i></p> <p><b>What's New in Monoclonal Antibodies</b> Speaker: <i>Juliane Bubeck-Wardenburg, M.D., Ph.D., Washington University</i></p> <p><b>Mining Microorganisms for Antibiotic Discovery</b> Speaker: <i>Rolf Mueller, Pharm.D., Ph.D., Helmholtz Pharmaceutical</i></p>
10:30 a.m.–10:45 a.m.	<p><b>Morning Refreshment Break</b></p> <p>📍 Nikko</p>
10:45 a.m.–12:15 p.m.	<p><b>Poster Session #2</b></p> <p>📍 Nikko</p>
11 a.m.–12 p.m.	<p><b>Partnerships, Policy, and PASTEUR—Oh My! Opportunities to Advance AMR Policy and Beyond</b></p> <p>📍 Congo I, II, III, &amp; IV</p> <p><b>Panel Discussion</b> Speakers: <i>Amalia Corby, M.S., American Society for Microbiology; Michael Craig, MPP, US Centers for Disease Control &amp; Prevention; Amanda Jezek, Infectious Diseases Society of America</i></p>
11:30–12:15 p.m.	<p><b>Lunch</b></p> <p>📍 Clyde and Nikko</p>

12:30–1:45 p.m.

## Plenary Session and Closing Lecture

📍 Congo I, II, III, & IV

Moderators: Cesar A. Arias, M.D., MSc, Ph.D., *Houston Methodist and Weill Cornell Medical College, IMARI 2026 Co-Chair*; Greg Moeck, Ph.D., *IMARI 2026 Co-Chair*

12:30–1:15 p.m.

### Outstanding Oral Abstract Presentations

12:30–12:45 p.m.

#### **Emergence and Genomic Context of Aztreonam–Avibactam Non-Susceptibility in Metallo- $\beta$ -Lactamase-Producing *Escherichia coli* in Michigan**

Presenter: Karla Vasco, *Michigan Department of Health & Human Services*

12:45–1 p.m.

#### **Base Excision Repair Deficiency Drives Highly Specific Mutagenesis and Rapid Drug Resistance Acquisition in *Pseudomonas aeruginosa***

Presenter: Kalen Hall, *Informuta, Inc.*

1–1:15 p.m.

#### **Direct-from-Blood Molecular Diagnostic for Detection of Bloodstream Pathogens and Antimicrobial Resistant Markers in ~ 1 Hour**

Presenter: Kimberle Chapin, *Deepull Diagnostics*


1:15–1:45 p.m.

### **Looking Ahead: The Next Era of AMR Research and Discovery**

Speaker: Eric Brown, Ph.D., *McMaster University*

# The Journal of Infectious Diseases

*The Journal of Infectious Diseases* (JID) publishes bench-to-bedside or bedside-to-bench translational infectious diseases science—patient- and disease-focused research featuring a laboratory component.



## Publish with impact

### Benefits for our authors:

#### High impact and visibility

With a CiteScore (Scopus) of 11.1 and an Impact Factor (Clarivate) of 4.5

#### Fast publication speeds

JID is committed to timely peer review, and accepted manuscripts are published within 24-72 hours

#### Review pathway for FIDSA

Fellows of the IDSA can submit a paper once per calendar year and receive guaranteed peer review

#### Distinguished Editorial Board

Led by Editor-in-Chief Cynthia L. Sears, MD, FIDSA

#### Open access options

With potential funding options via our publishing partner, Oxford University Press



Find out  
more today

# Abstracts

## Abstract Submission Topics

IMARI 2026 abstracts are organized under the following topic areas:

1.  $\beta$ -lactamases
2. Early Clinical Studies
3. Mechanisms of Resistance in Fungi
4. Mechanisms of Resistance in Gram Negative Bacteria
5. Mechanisms of Resistance in Gram Positive Bacteria
6. Mycobacteriology
7. New Antibacterials and Mechanisms of Action

8. New Antifungals
9. New Targets
10. Non-Traditional Approaches for AMR
11. Novel Diagnostics for AMR
12. PK/PD Antibacterial and Antifungals
13. Epidemiology and Surveillance

TOPIC (Poster topic or category)  
THURS/FRI (Day the poster is presented)  
200 (Assigned poster board number)

## Poster Session #1

📍 Nikko

Thursday, January 29

12:30–2 p.m.

TOPIC1-THURS-201

**Comprehensive Standardized Numbering and Alignment of the KPC Family of  $\beta$ -Lactamases**

Robert Bonomo, Case Western Reserve University School of Medicine

TOPIC1-THURS-202

**Comparative-effectiveness of Antibiotics Used to Treat Inpatients With Infective Endocarditis Due to Methicillin-susceptible *Staphylococcus aureus***

Corbyn Gilmore, University of Texas at Austin

TOPIC1-THURS-203

**Characterization of Extended-spectrum  $\beta$ -lactamase (ESBL)-producing Bacterial Populations Conferring Resistance to Cefotiofur from Dairy Cattle**

Danielle Gregory, Michigan State University

TOPIC1-THURS-204

**Structure Based Development of Cross-Class Carbapenemase Inhibitors**

Lian Jacobs, University of South Florida

TOPIC1-THURS-205

**Impact of Acquired Broad-Spectrum  $\beta$ -Lactamases on Susceptibility to Oral Cephalosporin (Ceftibuten) and Oral Carbapenem (Tebipenem) in Combination with New  $\beta$ -lactamase Inhibitors Ledaborbactam and Xeruborbactam in *Escherichia Coli***

Laurent Poirel, Medical and Molecular Microbiology Unit

TOPIC11-THURS-206

**Prediction of Antibiotic Susceptibility in *Acinetobacter baumannii* Using Genomic Mutational Signatures**

Ryan Shields, University of Pittsburgh

TOPIC1-THURS-207

**Kinetic and Structural Characterization of LRA-13, a Bifunctional  $\beta$ -lactamase from an Alaskan Soil Metagenome**

Pablo Power, *Universidad de Buenos Aires*

TOPIC1-THURS-208

**First Structural Insights into Thanatin as a Dual Inhibitor of NDM-1 and VIM-2 Metallo- $\beta$ -lactamases**

Gwladys Riviere, *University of California Riverside*

TOPIC3-THURS-209

**Previously Unrecognized Gut Colonization and Secondary Bile Acid Tolerance of *Candidozyma auris* in Critically Ill Patients**

Luisannys Lozada Pinto, *Houston Methodist Research Institute*

TOPIC10-THURS-210

**In Vitro and Ex Vivo Efficacy of a Novel Rosenblumvirus Phage to Treat *Staphylococcus aureus* keratitis**

Paulo Bispo, *Mass. Eye and Ear*

TOPIC4-THURS-211

**Transferable  $\beta$ -lactam Resistance in Multidrug-Resistant *Enterococcus faecalis* Via Truncation of *pbp4* and Acquisition of a Novel PBP (PBP-4a) Gene**

Guillermo Hoppe-Elsholz, *Weill Cornell Medical College*

TOPIC11-THURS-212

**Evaluation of ASTar Remnant Bacterial Suspension for Lateral Flow Immunoassay Genotypic Expression in Gram-negative Resistant Contrived Blood Cultures**

Vikas Gupta, *Q-linea*

TOPIC4-THURS-213

**Altered Porin Expression in *Klebsiella pneumoniae* Induces Resistance to Combination Treatment with Antibiotics and Biofilm Disrupting Surgical Lavage**

Terri Ellis, *University of North Florida*

TOPIC4-THURS-214

**A Novel Mechanism of Ceftolozane-tazobactam Resistance in *Pseudomonas aeruginosa* Mediated by L2 beta-lactamase**

Preeti Garai, *Northwestern University*

TOPIC4-THURS-215

**Functional Association Between RND Efflux Transporters and Pathogenicity in *Pseudomonas aeruginosa***

Laiba Ajmal, *University of Oklahoma*

TOPIC4-THURS-216

**Abstract Title: Phenotypic and Genotypic Characterization of Antimicrobial Resistance (AMR) Strains from the ATCC® Collection: A Key Resource for Diagnostics and Therapeutic Development**

Shahin Ali, *ATCC*

TOPIC4-THURS-217

**The Role of Bacteriostatic Antibiotics in Persister Cell Survival in *Escherichia coli***

Ruqayyah Amaratunga, *South Dakota State University*

TOPIC4-THURS-218

**Evidence for Reverse Zoonosis of Carbapenem-resistant *Klebsiella pneumoniae* ST307 Leading to Dog Infections and Establishment in a Veterinary Hospital**

Cooper Brookshire, *Mississippi State University*

TOPIC4-THURS-219

**Impact of Emergent *Escherichia coli* PBP3 Amino Acid Insertions on beta-Lactam Susceptibility**

Yohei Doi, *University of Pittsburgh*

TOPIC4-THURS-220

**Regulation of PBP1A and Coordination of Cell Division in *Acinetobacter baumannii***

Hanling Gong, *University of Texas at Dallas*

TOPIC4-THURS-221

**An Outer Membrane Porin Supports Lipid Asymmetry Maintenance in *Acinetobacter Baumannii***

Vineeth Hari Prasad, *University of Texas at Dallas*

TOPIC4-THURS-222

**Affinity and Kinetic Characterization of LiaX–PBP4 Interactions Underlying the Seesaw Effect in *Enterococcus faecalis***

Kara Hood, *Houston Methodist Research Institute*

TOPIC4-THURS-223

**Avibactam Preexposure Confers Zidebactam Resistance in NDM-Producing *Escherichia coli* but Preserves Synergistic Inhibition by Cefepime-Zidebactam**

Donghoon Alex Kang, *Houston Methodist Research Institute*

TOPIC4-THURS-224

**Effect of Conjugated IncX3 Plasmid Carrying Carbapenemase Revealed by Metabolomic and Phenotypic Profiling**

Su Min Kyung, *Seoul National University*

TOPIC4-THURS-225

**Antibacterial Activity and Intracellular Accumulation of Oxazolidinones in Gram-negative ESKAPE Pathogens**

Inga Leus, *University of Oklahoma*

TOPIC4-THURS-226

**Emergence of Cefiderocol Resistance from Heteroresistant *Pseudomonas aeruginosa* at Human Simulated Cefiderocol Exposure in a Hollow Fiber Model**

Nazanin Pouya, *University of Houston*

TOPIC4-THURS-227

**Bactericidal and anti-adhesion activity of Lacticaseibacillus rhamnosus CRL 2244 metabolites against methicillin-resistant *Staphylococcus aureus***

Maria Soledad Ramírez, *CSUF*

TOPIC13-THURS-228

**Burden of HAI-related Microbiota on ICU High-touch Surfaces Before and After the Opening of a New Healthcare Institution in Colombia**

Karen Ordoñez Diaz, *Hospital San Jorge de Pereira*

TOPIC4-THURS-229

**To Confirm or Not to Confirm, That is the Question: Performance of Vitek2 and Etest for Ertapenem, Meropenem, and Cefepime**

Felicia Rice, *Mayo Clinic Hospital*

TOPIC4-THURS-230

**Molecular Characteristics of Cefiderocol-Resistant IMP-type Carbapenemase-Producing *Enterobacter cloacae* Complex**

Satowa Suzuki, *Japan Institute for Health Security*

TOPIC4-THURS-231

**The Association Between Undetected Heteroresistance and Antibiotic Treatment Failure in Complicated Urinary Tract Infection**

Sushma Timalsina, *Emory University*

TOPIC4-THURS-232

**Mapping the Colistin Resistome of Clinical *Pseudomonas aeruginosa* Isolate BWH047**

Madeleine Vessely, *Northwestern University*

TOPIC5-THURS-233

**Functional Characterization of MmpL7 Reveals Lipid Transport, Flippase Activity, and Drug-Specific Inhibition Profile**

Svitlana Babii, *University of Oklahoma*

TOPIC5-THURS-234

**Post-fluoroquinolone treatment molecular events and nutrient availability modulate *Staphylococcus aureus* antibiotic persistence**

Jonathan Batchelder, *University of Connecticut Health Center*

TOPIC5-THURS-235

**Role of Stk1 in antibiotic resistance in *Staphylococcus aureus***

*Swagata Bose, University of Maryland Baltimore*

TOPIC5-THURS-236

**Genetic and Phenotypic Investigation of Clinical Isolates from Cases of MRSA Bacteremia with Antibiotic Treatment Failure who Received Salvage Therapy**

*Jeffrey Freiberg, Vanderbilt University Medical Center*

TOPIC5-THURS-237

**Hypermutator *Enterococcus faecalis* Displays a Distinct Mutational Signature and Rapid Antibiotic Resistance Acquisition**

*Kalen Hall, Informuta, Inc.*

TOPIC5-THURS-238

**Mcr-1 Plasmids Confer Both Colistin Resistance and Virulence via Surface-Polysaccharide Remodeling in *Escherichia coli***

*Byeonghwa Jeon, University of Minnesota*

TOPIC5-THURS-239

**LiaX Surface Expression in *Enterococcus faecalis* (Efs) Endocarditis Isolates With and Without GelE Metalloprotease and Daptomycin (DAP) susceptibility**

*Diana Panesso-Botero, Center for Infectious Diseases*

TOPIC5-THURS-240

**Prediction Of Antimicrobial Susceptibility from Genomic Determinants in *Staphylococcus aureus***

*Shanita Smrity, University of Georgia*

TOPIC5-THURS-241

**LiaX ELISA Predicts Daptomycin (DAP) Efficacy in *Enterococcus faecium* Independent of Minimum Inhibitory Concentration (MIC) Values**

*Truc Tran, Houston Methodist Research Institute*

TOPIC5-THURS-242

**Integrated Multi-omics Analysis of a Single Nucleotide Variant in *walk* that Drives Cross-resistance to Vancomycin, Daptomycin, and Dalbavancin in *S. aureus*.**

*Brian Werth, University of Washington School of Pharmacy*

TOPIC7-THURS-243

**Abstract Title: A Natural Antibiotic That Curtails Cell Envelope Adaptation and Evolution of Resistance in Multidrug-Resistant *Enterococcus faecalis***

*Domenica Acevedo, Houston Methodist*

TOPIC7-THURS-245

**FPI-2119 Bactericidal Activity and Resistance Selection in Enterobacteriales**

*Karen Bush, Indiana University*

TOPIC7-THURS-246

**Advancing Development of a Novel Therapeutic to Rescue Frontline Antibiotic Treatment of Bacterial Pneumonia**

*Bliss Cunningham, University of Melbourne*

TOPIC7-THURS-247

**Target Identification and Mechanism of Action Elucidation of *Pseudomonas aeruginosa*-specific inhibitor.**

*Arun Dahal, University of Oklahoma*

TOPIC7-THURS-248

**From Bench to Breath: Aerosolized AMP OMN51 as a First-Line Therapy for Chronic Lung Infections**

*Niv Bachnoff, Omnitix Medical*

TOPIC7-THURS-249

**In Vitro Evaluation of Novel Heterocyclic Compounds Active Against *Neisseria gonorrhoeae***

*Maria del Pilar Crespo-Ortiz, Universidad del Valle*

TOPIC8-THURS-250

**Real-World Antifungal Susceptibility Testing of Ibrexafungerp Against Candida Species Through the CDC Antimicrobial Resistance Laboratory Network, United States, 2023–2024**

Meghan Lyman, *Centers for Disease Control and Prevention*

TOPIC7-THURS-251

**In Vitro Evaluation of Next-Generation Microbicide EQ12 as a Topical Treatment for Drug-Resistant Skin and Soft Tissue Infections**

Madelyn Kist, *Tulane University School of Medicine*

TOPIC7-THURS-252

**Efficacy of FPI-2119 Against Klebsiella pneumoniae in Murine Models of Bacterial Septicemia and Lung Infection**

Lynn Miesel, *Pharmacology Discovery Services Taiwan, Ltd.*

TOPIC7-THURS-253

**In Silico and AI-Guided Discovery of Novel Small-Molecule Protease Activators**

Roha Razzaq, *South Dakota State University*

TOPIC7-THURS-254

**In Vitro Activity of Fpi-2119 Against Multidrug-Resistant, Carbapenem-Producing Gram-Negative Pathogens: A First-in-Class Broad-Spectrum Antibacterial Agent**

Sameeh Salama, *Fedora Pharmaceuticals Inc.*

TOPIC7-THURS-255

**Penicillin-Binding Protein (PBP) Binding Patterns and Morphological Changes of Escherichia coli and Klebsiella pneumoniae in Response to a New, Non-B-Lactam PBP-Binder (FPI-2119)**

Alaa Sayed, *St. Jude Children's Research Hospital*

TOPIC7-THURS-256

**Novel Thrombin-Derived C-Terminal Stapled Antimicrobial Peptides Reduce Inflammation and Infection In Vitro and In Vivo**

Weiliang Xu, *PepLib*

TOPIC8-THURS-257

**Investigations on the Mechanism of Action of the Novel Anti-Fungal MBX-7591**

Keyla Ramirez Soto, *Dartmouth Geisel School of Medicine*

TOPIC8-THURS-258

**Small Molecule Inhibitors of Fungal Phosphoinositide Signaling Show Antimycotic Activity Against Nakaseomyces glabratus**

Ashley Kidwell, *Texas A&M University*

TOPIC9-THURS-259

**Turning Resistance into Weakness: Targeting Vulnerabilities Linked to  $\beta$ -Lactamase Overexpression in Acinetobacter baumannii**

Jennifer Colquhoun, *Department of Veterans Affairs*

TOPIC9-THURS-260

**Paralogous Proteins as Potential Antibiotic Multitargets in Mycobacterium tuberculosis**

Christine Hardy, *CDH Consulting*

TOPIC9-THURS-261

**Toward Optimizing the Ascending UTI Mouse Model for Evaluating DXPS Inhibitors**

Erika Serrano-Diaz, *Johns Hopkins University*

TOPIC9-THURS-262

**Covalent Inhibitors Targeting Type I Topoisomerases for Infectious Disease Treatments**

Yuk-Ching Tse-Dinh, *Florida International University*

TOPIC13-THURS-263

**Changes in the In Vitro Activity of Oral Agents Against Isolates of Community-acquired Pathogens from Respiratory Infections in Patients  $\geq 65$  Years Old Before, During, and After the COVID-19 Pandemic**

Alona Kuraieva, *Pfizer, Inc.*

TOPIC 12-THURS-264

**Clinical Implications of Multidrug-Resistant Bacterial and Fungal Co-Infections in ICU Patients: Insights from the DYNAMITE Cohort**

Marissa Schettino, *Houston Methodist Hospital*

TOPIC 12-THURS-265

**Potent Synergy of Dual  $\beta$ -Lactams Against *Mycobacterium avium* Complex**

Eunjeong Shin, *Case Western Reserve University*

TOPIC10-THURS-266

**PASTEUR and Beyond—Advancing AMR Policy in Challenging Times**

Amalia Corby, *American Society for Microbiology*



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY

Journals.ASM.org

## ASM JOURNALS

### *Essential in the fight against Antimicrobial Resistance.*

Visit our table to speak to ASM staff about publishing your research and learn more about our wide breadth of journals.

Explore Current  
Calls for Papers



Join one of ASM's  
Editorial Boards



Dive Deeper With Webinars

- mSystems® Thinking Series
- Journal of Virology® Seminar Series
- JMBE Live!



Connect at Global  
Scientific Meetings



Collection: Antimicrobial  
Resistance in India



# IMARI

Interdisciplinary Meeting  
on Antimicrobial Resistance  
and Innovation



**ASM is Increasing Access  
Through Subscribe to Open!**

Learn about S2O!  
[journals.asm.org/S2O](http://journals.asm.org/S2O)



Questions? Contact [journals@asmusa.org](mailto:journals@asmusa.org)

## Poster Session #2

Friday, January 30

10:45 a.m.–12:15 p.m.

TOPIC2-FRI-201

**Microbial Community Clustering of The Gut Microbiome in Critically Ill Patients Identifies Patients at High Risk of Poor Outcomes**

Hossaena Ayele, *University of Texas Health Science Center at Houston*

TOPIC2-FRI-202

**Clinical Impact and Genomic Features of B-Lactam Heteroresistance (HR) Among Hematologic Malignancy Patients With *Pseudomonas Aeruginosa* Bacteremia**

Stephanie Egge, *Oregon Health & Science University*

TOPIC2-FRI-203

**Multi-omics Reveal Gut Microbiome and Bile Acid Preservation in a Phase 2 Clinical Trial Comparing CRS3123 to Vancomycin for *C. difficile* Infection**

Laurie Lyon, *University of Colorado Anschutz*

TOPIC2-FRI-204

**Antibiotic Exposure and Colonization with Multidrug-Resistant Organisms in ICU Patients: Insights from the DYNAMITE Cohort**

Giselle Ortiz, *Houston Methodist*

TOPIC2-FRI-205

**Preferred management strategies for Carbapenem-Resistant *A. baumannii* (CRAB) in the United States: Insights from the PRECEDENT Network**

Ryan Shields, *University of Pittsburgh*

TOPIC2-FRI-206

**Coming into Resistance: Characterizing Taxa Driving Clinically-Important Antibiotic Resistance Genes in NICU Infants versus Healthy Infants**

Rachel Strength, *NIH/NIAID*

TOPIC2-FRI-207

**Elevated Sulbactam-durlobactam Resistance in Carbapenem-resistant *Acinetobacter baumannii* (CRAB) at an Ohio Institution**

Hillary Van Heule, *Cleveland Clinic*

TOPIC2-FRI-208

**Actionable Changes and Outcomes from Rapid Phenotypic Antimicrobial Susceptibility Testing in Hospitalized Patients with Bloodstream Infection**

Rebecca Yee, *George Washington University School of Medicine and Health Sciences*

TOPIC6-FRI-209

**Protein Engineering and Chemical Labelling in Service of Mycobacterial Lipoprotein Trafficking System Identification**

Sille Remm, *Harvard T.H. Chan School of Public Health*

TOPIC6-FRI-210

**Efficacy of Drug Regimens Containing Omadacycline in a Murine Model of *Mycobacterium avium* Chronic Lung Infection**

Alisa Serio, *Paratek Pharmaceuticals, Inc.*

TOPIC6-FRI-211

**Structural Basis of Potency and Target Binding of Novel Carbapenem Candidates in Nontuberculous Mycobacteria**

Eunjeong Shin, Case Western Reserve University

TOPIC10-FRI-212

**Solving The Great Plate Count Anomaly: Discovery of an Antimicrobial Compound Against Multidrug-Resistant *Staphylococcus* spp.**

Donnie Alverson, Oregon State University

TOPIC12-FRI-213

**Utilizing a Simultaneous Neutropenic Thigh and Hematogenous Pyelonephritis Mouse Model to Determine PK/PD Efficacy of a Novel LpxC Inhibitor FG-2101**

Alexander Lepak, University of Wisconsin

TOPIC10-FRI-214

**Density-Dependent, Non-Genetic Survival of *E. coli* Under Low-Level Antibiotic Stress**

Suchi Parvin Biki, South Dakota State University

TOPIC10-FRI-215

**Deep Learning Model to Identify Novel Antibacterial Compounds**

Kerry Buchholz, Genentech

TOPIC10-FRI-216

**Uncovering Gene Networks Driving Primed Cell-Mediated Antibiotic Persistence Across Growth Phases**

Manisha Guha, South Dakota State University

TOPIC7-FRI-217

**Novel Boron-based Bisthiazolidine as Potentially Potent Cross-class  $\beta$ -lactamase Inhibitors**

Robert Bonomo, Case Western Reserve University School of Medicine

TOPIC10-FRI-219

**Development of a Broad-spectrum Anti-Salmonella Vaccine**

Herbert Kavunja, Iaso Therapeutics

TOPIC10-FRI-220

**Therapeutic Effects of a Type 3 Secretion Inhibitor (MBX-5452A) in *P. aeruginosa* Pneumonia**

Timothy Opperman, Microbiotix, Inc.

TOPIC10-FRI-221

**Inhibition of FimH-Mediated *Escherichia coli* Adhesion by Cranberry-Derived Phenolic Compounds and D-Mannose**

Tomislav Mestrovic, University North

TOPIC10-FRI-222

**In Vitro Antimicrobial and Antibiofilm Activity of a Novel Bacteriophage Combined With Vancomycin Against *Staphylococcus aureus* from Endophthalmitis**

Paulo Bispo, Massachusetts Eye and Ear

TOPIC10-FRI-224

**Activity of a Novel Phikmvirus Phage Used Alone or With Polymyxin B Against XDR *Pseudomonas aeruginosa* From a Keratitis Outbreak**

Bridget Slomka, Massachusetts Eye and Ear

TOPIC10-FRI-225

**Immunometabolic Modulation Enhances Antibiotic-Mediated Intracellular *Staphylococcus aureus* Clearance**

Emma Stockton, University of Southern California

TOPIC10-FRI-226

**A Novel Bacteriophage Lysin-human Defensin Fusion Protein is Effective in Treatment of *Clostridioides difficile* Infection in Mice**

Xingmin Sun, University of South Florida

TOPIC10-FRI-227

**Targeting Multidrug-Resistant *Stenotrophomonas maltophilia*: Novel Approaches for a Rising Threat**

Anthony Valletta, *Duquesne University*

TOPIC10-FRI-228

**A Counterfactual Machine Learning Approach for Evaluating AMR Policy Interventions**

Claire Vania, *Johns Hopkins University*

TOPIC10-FRI-229

**Novel Synthetic EGCG Analog Protects Neutrophils from *Staphylococcus aureus* Virulence Factor-Mediated Killing**

Xingfan Wu, *University of Southern California*

TOPIC11-FRI-230

**Direct-from-Blood Molecular Diagnostic for Detection of Bloodstream Pathogens and Antimicrobial Resistant Markers in ~ 1 Hour**

Kimberle Chapin, *Deepull Diagnostics*

TOPIC11-FRI-231

**A Novel Rapid Molecular-Phenotypic Assay for Viability and Antibiotic Susceptibility Assessment of *Neisseria Gonorrhoeae* (NG) Direct From Patient Samples**

Tamika Blair, *SpeeDx*

TOPIC11-FRI-232

**Developing Predictive Models for Antimicrobial Susceptibility in *Neisseria Gonorrhoeae***

Pavani Bommane, *University of Georgia*

TOPIC11-FRI-233

**Independent Prediction of Ampicillin MIC Using *pbp5* Allele Classification in *Enterococcus faecium*: A Prospective Validation Cohort from VENOUS**

Cheyenne Bright, *Weill Cornell-Houston Methodist Research Institute*

TOPIC11-FRI-234

**Evaluation of KWIK-STIK™ for Streamlined Quality Control on the ASTar® System**

Natalie Brown, *Q-linea*

TOPIC11-FRI-235

**A Pooled Performance and Adjudication Analysis of ASTar® Rapid Antimicrobial Susceptibility Testing System from Gram-negative Positive Blood Cultures**

Vikas Gupta, *Q-linea*

TOPIC11-FRI-237

**Microbial-derived Volatile Organic Compounds as Diagnostic Biomarkers of Pulmonary Infections**

Ebuka David, *Federal University of Sao Paulo*

TOPIC11-FRI-238

**Overestimation of Echinocandin and Amphotericin B Resistance by Sensititre YeastOne in *Candidozayma auris***

Luisannys Lozada Pinto, *Houston Methodist Research Institute*

TOPIC11-FRI-239

**A Lateral Flow-based Phenotypic Rapid Antibiotic Susceptibility Test**

Emily Melzer, *Latde Diagnostics*

TOPIC11-FRI-240

**First Documented Case of hVISA in a Patient With Chronic Kidney Disease With Cardiovascular Complications in Colombia: A Clinical Challenge**

Karen Ordoñez Diaz, *Hospital San Jorge de Pereira*

TOPIC1-FRI-242

**Evolutionary Potential of OXA-163  $\beta$ -lactamase Toward Ceftazidime/ Avibactam Resistance**

Pablo Power, *Universidad de Buenos Aires*

TOPIC13-FRI-243

**Prevalence of  $\beta$ -lactam Antibiotics Resistance in Neonatal *Escherichia coli* Septicemia Isolates: Findings from the NEAR-ME Collaborative**

Indira Maheshwari Elangovan, *Children's Mercy Hospital*

TOPIC13-FRI-244

**Characterization of a Rare Hospital-Associated Snowbird MRSA Lineage**

Emily Felton, *University of South Florida*

TOPIC13-FRI-245

**Using Genomic Epidemiology to Understand the Spread of Antimicrobial Resistance Among Clinical *Shigella* spp**

Kyleen Hall, *Michigan State University*

TOPIC13-FRI-246

**Geographic Variation in ESBL Genotype and Phenotype in UTI Diagnostic Testing**

Ibrahim Hashim, *UT Southwestern Medical Center*

TOPIC13-FRI-247

**Changes in the In Vitro Activity of Intravenous Antimicrobial Agents Against Hospital-acquired Gram-negative Bacilli Causing Respiratory Infections in Patients  $\geq 65$  Years Old Before, During, and After the COVID-19 Pandemic**

Alona Kuraieva, *Pfizer, Inc.*

TOPIC4-FRI-248

**Klebsiella pneumoniae Under Cefiderocol Pressure: Longitudinal Phenotypic and Genotypic Dynamics**

German Traglia, *Universidad de la Republica*

TOPIC13-FRI-249

**Mercury Resistant Genes Contribute to Adaptive Advantage in USA300-LV Latin American Variant MRSA Exposed to Subinhibitory Concentrations of Mercury**

Jinnethé Reyes, *Pontificia Universidad Javeriana*

TOPIC13-FRI-250

**Whole-Genome Characterization of ST410 *Escherichia coli* Carrying Carbapenemase-Producing IncFII Plasmids Shared by Human and Companion Dogs**

Eunseo Lee, *Seoul National University*

TOPIC13-FRI-251

**Emerging Patterns of the Cefazolin Inoculum Effect (CzIE) in *Staphylococcus aureus*: Implications for Therapy in the USA and Latin America**

Diana Panesso, *Houston Methodist Research Institute*

Poster Board Number: TOPIC13-FRI-252

**Trends in Antifungal Resistance Among Candida Species in the United States, 2015 – 2024**

Maria Pérez Ardila, *Houston Methodist Research Institute*

TOPIC13-FRI-253

**Emergence of MRSA ST72/SCCmec-V in a High-Complexity Hospital in Pereira, Colombia: First Report of hVISA and Rising Daptomycin Resistance.**

Jinnethé Reyes, *Pontificia Universidad Javeriana*

TOPIC13-FRI-254

**AMR Register: A Freely Accessible Platform for Global Industry AMR Surveillance Data**

Amanda Skarupka, *Vivli*

TOPIC13-FRI-255

**Clinical Outcomes and Molecular Epidemiology of Ampicillin-susceptible *Enterococcus faecium* Bloodstream Infection: A Sub-analysis of the VENOUS II Cohort**

Truc Tran, *Houston Methodist Research Institute*

TOPIC4-FRI-256

**Iron and Vitamin B12 TonB-dependent Receptors (TBDRs) Crosstalk Shapes Cefiderocol Susceptibility in Gram-Negative Bacteria**

Maria Soledad Ramirez, CSUF

TOPIC4-FRI-257

**Base Excision Repair Deficiency Drives Highly Specific Mutagenesis and Rapid Drug Resistance Acquisition in *Pseudomonas aeruginosa***

Kalen Hall, *Informuta, Inc.*

TOPIC4-FRI-258

**Emergence and Genomic Context of Aztreonam-avibactam Non-susceptibility in Metallo- $\beta$ -lactamase-producing *Escherichia coli* in Michigan**

Karla Vasco, *Michigan Department of Health & Human Services*

TOPIC11-FRI-259

**Uptake of Rapid Diagnostics for Antimicrobial Resistance Detection Using Nucleic Acid Amplification in U.S. Hospitals 2018-2024**

Vamsi Chodisetty, *National Institute of Health*

TOPIC13-FRI-260

**Public Health Efforts to Detect Azole-Resistant *Aspergillus fumigatus* in U.S. Patients**

Luisa Lopez Cano, *Centers for Disease Control and Prevention*

NEW AGENTS-FRI-261

**Compound SCY-247**

David Angulo, *SCYNEXIS, Inc.*

NEW AGENTS-FRI-262

**Compound FG-2101**

Andrew Tomaras, *Blacksmith Medicines*

NEW AGENTS-FRI-263

**Compound SER-155**

Dennis Walling, *Seres Therapeutics*

NEW AGENTS-FRI-264

**Compound Zosurabalin**

Michael Lobritz, *Roche*

NEW AGENTS-FRI-265

**Compound Turletricin/EL219**

Taylor Sandison, *Elion Therapeutics*